PCI Pharma Services Capabilities Update March 2026: Small Molecule Drug Product

This presentation highlights PCI Pharma Services’ capabilities in the development, manufacturing, and packaging of ultra-high potent oral solid dose and liquid products, with a focus on recent strategic investments that have significantly expanded contained manufacturing, high-potency handling, and analytical capacity.

Attendees will gain insight into PCI’s SMART FHD™ approach, designed to accelerate early-phase development through streamlined first-human-dose readiness, as well as its integrated partner network supporting advanced solubility enhancement technologies for targeted protein degraders (TPDs). The session will also showcase current multi-product capacity and flexible infrastructure, enabling rapid progression from early development through commercial supply while maintaining the highest standards of safety, quality, and containment.